Camlin Fine Sciences Navigates Q3 FY26 with Strategic Acquisitions and Tariff Shifts

Camlin Fine Sciences Limited, a prominent player in the specialty chemicals sector, recently announced its financial results for the third quarter and nine months ended December 31, 2025 (Q3 FY26). The company reported a consolidated revenue from operations of Rs. 457.2 crores for Q3 FY26, marking a 6.1% year-on-year growth. However, the quarter presented a mixed performance, with certain segments facing headwinds while strategic initiatives and other businesses demonstrated resilience and growth potential. The Adjusted EBITDA for Q3 FY26 stood at Rs. 30.72 crores, with a margin of 6.7%.

The operational revenue breakdown for the nine months of FY26 highlights the company's diversified portfolio. Specialty Ingredients (Value Added Blends) emerged as the largest contributor, accounting for 56% of the revenue with Rs. 745.6 crores. This segment continues to be a hallmark of the company's business, maintaining steady growth across key markets. Aroma Ingredients contributed 14% (Rs. 190.4 crores), while Specialty Ingredients (Straights) and Performance Chemicals contributed 19% (Rs. 247.8 crores) and 11% (Rs. 142.0 crores) respectively. The Straights business, however, faced pricing pressure and intense competition, impacting its profitability during the period. The Vanillin business, a key product, was impacted by tariff-related challenges, leading to controlled sales in the quarter to capitalize on anticipated higher realizations from tariff withdrawals in subsequent periods.

Strategic Moves and Growth Drivers

A significant development in Q3 FY26 was Camlin Fine Sciences' acquisition of a controlling stake in Vinpai, a French company specializing in natural functional ingredients. This strategic move is aimed at portfolio diversification, allowing CFSL to enter the high-growth natural ingredients space. Vinpai contributed Rs. 12.9 crores to the revenue in Q3 FY26, and management anticipates scaling up its topline by 40-50% in FY27. This acquisition is expected to leverage Vinpai's existing footprint across 36 countries, enhance R&D capabilities, and create cross-selling opportunities in the food, cosmetics, and nutraceutical industries.

Furthermore, the company's Vitafor business, acquired in June 2024, is also on a growth trajectory. Management expects Vitafor's topline to grow by 40-50% in FY27, from 12-13 million euros to 17-18 million euros, with product launches planned in the US, Mexico, Brazil, and India. This expansion aligns with the company's focus on animal nutrition and value-added blends.

Innovation remains a core pillar for Camlin Fine Sciences. The company is actively pursuing process optimization initiatives, including continuous improvements in Vanillin production at its Dahej plant and enhancing quality through instrumental analysis. Product development efforts are underway for high-quality hydroquinone and catechol downstream products, with antioxidant innovations already transitioning from R&D to market. The company also introduced new emulsifier-based ingredients to enhance texture and consistency in food industry applications, with several new specialty ingredients expected to be commercialized in FY26.

Navigating Challenges and Future Outlook

The quarter was not without its challenges. A fire incident was reported at one of the blending units in Brazil on February 7, 2026, resulting in the suspension of operations at that unit and loss of stock. While loss assessment and insurance claims are in progress, the company has stated it is adequately insured and is making alternative arrangements to service customers. Additionally, the company is in the process of liquidating its CFS Europe and China operations to curtail losses from discontinued businesses, which have been a source of cash burn. Management expects these liquidations to be finalized by the end of the financial year, eliminating future costs.

Despite these challenges, the management maintains a positive outlook. For FY27, the company has guided for a total Vanillin volume of 4,000 metric tons and expects the Blends business to grow by 25% over FY26. Consolidated revenue is projected to reach approximately Rs. 2,200 crores in FY27 and Rs. 2,400 crores in FY28, with Adjusted EBITDA margins expected to improve to 12-14%. The company also highlighted its commitment to ESG goals, aiming to switch to renewable electricity for all manufacturing facilities by 2030.

Camlin Fine Sciences is strategically positioning itself for future growth by focusing on high-value segments, leveraging acquisitions, and driving innovation, even as it addresses operational challenges and streamlines its global footprint. The emphasis on vertical integration and expanding its specialty ingredients portfolio underscores its commitment to sustained value creation.